Targeting stem cells in the realm of drug-resistant breast cancer

References

• SiegelRLMillerKDJemalACancer statistics, 2017CA Cancer J Clin201767173028055103
   PubMed Web of Science ®Google Scholar
• CurtisCShahSPChinS-FThe genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature2012486740334635222522925
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and PreventionCancers diagnosed at late-stages despite available screening tests [Press release] Available from: https://www.cdc.gov/media/pressrel/2010/r101124.htmlAccessed February 18, 2019
   Google Scholar
• HaqueRAhmedSAInzhakovaGImpact of breast cancer subtypes and treatment on survival: an analysis spanning two decadesCancer Epidemiol Biomarkers Prev201221101848185522989461
   PubMed Web of Science ®Google Scholar
• ReinertTBarriosCHOptimal management of hormone receptor positive metastatic breast cancer in 2016Ther Adv Med Oncol20157630432026557899
   PubMed Web of Science ®Google Scholar
• MehtaRSBarlowWEAlbainKSCombination anastrozole and fulvestrant in metastatic breast cancerN Engl J Med2012367543544422853014
   PubMed Web of Science ®Google Scholar
• WuerstleinRHarbeckNNeoadjuvant therapy for HER2-positive breast cancerRev Recent Clin Trials2017122819228164759
   PubMed Web of Science ®Google Scholar
• LehmannBDJovanovićBChenXRefinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selectionPLoS One2016116e015736827310713
   PubMed Web of Science ®Google Scholar
• BerradaNDelalogeSAndréFTreatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?Ann Oncol201021Suppl 7vii30vii3520943632
   PubMed Web of Science ®Google Scholar
• MillerTWHennessyBTGonzález-AnguloAMHyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancerJ Clin Invest201012072406241320530877
   PubMed Web of Science ®Google Scholar
• MillerTWRexerBNGarrettJTArteagaCLMutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancerBreast Cancer Res201113622422114931
   PubMed Web of Science ®Google Scholar
• BlackwellKBurrisHGomezPPhase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitorBreast Cancer Res Treat2015154228729726497877
   PubMed Web of Science ®Google Scholar
• di LeoASeok LeeKCiruelosEAbstract S4-07: BELLE-3: a phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatmentCancer Res2017774 SupplementS407
   Google Scholar
• BaselgaJCortésJDelaurentiisMSANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA- mutant tumorsJ Clin Oncol20173515_supplTPS1119
   Google Scholar
• SauraCde AzambujaEHlauschekDLBA10_PRPrimary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (let) plus taselisib versus let plus placebo (Pla) in postmenopausal patients (PTS) with ER+/HER2-negative early breast cancer (EBC)Ann Oncol201728suppl_5mdx440.001
   Google Scholar
• SchmidPPinderSEWheatleyDPhase II randomized preoperative Window-of-Opportunity study of the PI3K inhibitor Pictilisib plus anastrozole compared with anastrozole alone in patients with estrogen receptor-positive breast cancerJ Clin Oncol201634171987199426976426
   PubMed Web of Science ®Google Scholar
• BaselgaJCamponeMPiccartMEverolimus in postmenopausal hormone-receptor-positive advanced breast cancerN Engl J Med2012366652052922149876
   PubMed Web of Science ®Google Scholar
• FlemingGFMaCXHuoDPhase II trial of temsirolimus in patients with metastatic breast cancerBreast Cancer Res Treat2012136235536322245973
   PubMed Web of Science ®Google Scholar
• XuHYuSLiuQRecent advances of highly selective CDK4/6 inhibitors in breast cancerJ Hematol Oncol20171019728438180
   PubMed Web of Science ®Google Scholar
• ShahANCristofanilliMThe growing role of Cdk4/6 inhibitors in treating hormone receptor-positive advanced breast cancerCurr Treat Options Oncol2017181628197838
   PubMed Web of Science ®Google Scholar
• Barroso-SousaRShapiroGITolaneySMClinical development of the CDK4/6 inhibitors Ribociclib and Abemaciclib in breast cancerBreast Care201611316717327493615
   PubMed Web of Science ®Google Scholar
• SledgeGWToiMNevenPMONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapyJ Clin Oncol201735252875288428580882
   PubMed Web of Science ®Google Scholar
• AcharyaMRSparreboomAVenitzJFiggWDRational development of histone deacetylase inhibitors as anticancer agents: a reviewMol Pharmacol200568491793215955865
   PubMed Web of Science ®Google Scholar
• StanwaySJDelavaultPPurohitASteroid sulfatase: a new target for the endocrine therapy of breast cancerOncologist200712437037417470679
   PubMed Web of Science ®Google Scholar
• PalmieriCSteinRCLiuXIris study: a phase II study of the steroid sulfatase inhibitor irosustat when added to an aromatase inhibitor in ER-positive breast cancer patientsBreast Cancer Res Treat2017165234335328612226
   PubMed Web of Science ®Google Scholar
• RasmussenLMZaveriNTStenvangJPetersRHLykkesfeldtAEA novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancerBreast Cancer Res Treat2007106219120317268816
   PubMed Web of Science ®Google Scholar
• GuerinMRezaiKIsambertNPIKHER2: a phase Ib study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancerEur J Cancer201786283628950146
   PubMed Web of Science ®Google Scholar
• SauraCBendellJJerusalemGPhase Ib study of Buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapyClin Cancer Res20142071935194524470511
   PubMed Web of Science ®Google Scholar
• TolaneySBurrisHGartnerEPhase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancerBreast Cancer Res Treat2015149115116125537644
   PubMed Web of Science ®Google Scholar
• HudisCSwantonCJanjigianYYA phase 1 study evaluating the combination of an allosteric Akt inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumorsBreast Cancer Res2013156R11024252402
   PubMed Web of Science ®Google Scholar
• HurvitzSAAndreFJiangZCombination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trialLancet Oncol201516781682926092818
   PubMed Web of Science ®Google Scholar
• Acevedo-GadeaCHatzisCChungGSirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapyBreast Cancer Res Treat2015150115716725687356
   PubMed Web of Science ®Google Scholar
• SeilerMRay-CoquardIMelicharBOral ridaforolimus plus trastuzumab for patients with HER2+ trastuzumab-refractory metastatic breast cancerClin Breast Cancer2015151606525239224
   PubMed Web of Science ®Google Scholar
• NahtaREstevaFJHER2 therapy: molecular mechanisms of trastuzumab resistanceBreast Cancer Res20068621517096862
   PubMed Web of Science ®Google Scholar
• HettmanTSchneiderMBlumSAbstract B161: U3-1287 (AMG 888), a fully human anti-HER3 mAb, demonstrates preclinical efficacy in HER2+ and HER2− breast cancer modelsMol Cancer Ther20098Supplement 1B161
   Web of Science ®Google Scholar
• ChanADelalogeSHolmesFANeratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncol201617336737726874901
   PubMed Web of Science ®Google Scholar
• MukaiHSaekiTAogiKPatritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancerCancer Sci2016107101465147027452985
   PubMed Web of Science ®Google Scholar
• BangYJGiacconeGImSAFirst-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumorsAnn Oncol20172885586128119295
   PubMed Web of Science ®Google Scholar
• DiérasVBachelotTThe success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancerTarget Oncol20149211112223852665
   PubMed Web of Science ®Google Scholar
• LianosGDVlachosKZorasORoukosDHPotential of antibody-drug conjugates and novel therapeutics in breast cancer managementOnco Targets Ther2014749124711706
   PubMed Web of Science ®Google Scholar
• MittendorfEACliftonGTHolmesJPFinal report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patientsAnn Oncol20142591735174224907636
   PubMed Web of Science ®Google Scholar
• LimentaniSACamponeMDorvalTA non-randomized dose-escalation phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumorsBreast Cancer Res Treat2016156231933026993131
   PubMed Web of Science ®Google Scholar
• HamiltonEBlackwellKHobeikaACPhase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]J Transl Med2012102822325452
   PubMed Web of Science ®Google Scholar
• LinderholmBKHellborgHJohanssonUSignificantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancerAnn Oncol200920101639164619549711
   PubMed Web of Science ®Google Scholar
• RobertNJDiérasVGlaspyJRIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancerJ Clin Oncol201129101252126021383283
   PubMed Web of Science ®Google Scholar
• CastrellonABPidhoreckyIValeroVRaezLEThe role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancerOncol Rev2017111
   Web of Science ®Google Scholar
• RobsonMImSASenkusEOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA MutationN Engl J Med2017377652353328578601
   PubMed Web of Science ®Google Scholar
• BryantHESchultzNThomasHDSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature2005434703591391715829966
   PubMed Web of Science ®Google Scholar
• BrownJSKayeSBYapTAPARP inhibitors: the race is onBr J Cancer2016114771371527022824
   PubMed Web of Science ®Google Scholar
• TurnerNCTelliMLRugoHSFinal results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO)J Clin Oncol20173515_suppl1007
   Web of Science ®Google Scholar
• TimmsKMAbkevichVHughesEAssociation of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypesBreast Cancer Res201416647525475740
   PubMed Web of Science ®Google Scholar
• CareyLARugoHSMarcomPKTBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancerJ Clin Oncol201230212615262322665533
   PubMed Web of Science ®Google Scholar
• BaselgaJGómezPGreilRRandomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancerJ Clin Oncol201331202586259223733761
   PubMed Web of Science ®Google Scholar
• TomaoFPapaAZaccarelliETriple-negative breast cancer: new perspectives for targeted therapiesOnco Targets Ther2015817725653541
   PubMed Web of Science ®Google Scholar
• FinnRSBengalaCIbrahimNDasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 studyClin Cancer Res201117216905691322028489
   PubMed Web of Science ®Google Scholar
• KimEMMuellerKGartnerEBoernerJDasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cellsJ Surg Res2013185123123923899511
   PubMed Web of Science ®Google Scholar
• RoseAANBiondiniMCurielRSiegelPMTargeting GPNMB with glembatumumab vedotin: current developments and future opportunities for the treatment of cancerPharmacol Ther201717912714128546082
   PubMed Web of Science ®Google Scholar
• RoseAAGrossetAADongZGlycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancerClin Cancer Res20101672147215620215530
   PubMed Web of Science ®Google Scholar
• YardleyDAWeaverRMeliskoMEEmerge: a randomized phase II study of the antibody-drug conjugate Glembatumumab Vedotin in advanced glycoprotein NMB-Expressing breast cancerJ Clin Oncol201533141609161925847941
   PubMed Web of Science ®Google Scholar
• HanahanDWeinbergRAHallmarks of cancer: the next generationCell2011144564667421376230
   PubMed Web of Science ®Google Scholar
• NowellPCThe clonal evolution of tumor cell populationsScience197619442602328959840
   PubMed Web of Science ®Google Scholar
• KresoADickJEEvolution of the cancer stem cell modelCell Stem Cell201414327529124607403
   PubMed Web of Science ®Google Scholar
• Al-HajjMWichaMSBenito-HernandezAMorrisonSJClarkeMFProspective identification of tumorigenic breast cancer cellsProc Natl Acad Sci USA200310073983398812629218
   PubMed Web of Science ®Google Scholar
• ChekhunSVZadvornyTVTymovskaYOCD44+/CD24- markers of cancer stem cells in patients with breast cancer of different molecular subtypesExp Oncol2015371586325804234
   PubMedGoogle Scholar
• MuñozPIliouMSEstellerMEpigenetic alterations involved in cancer stem cell reprogrammingMol Oncol20126662063623141800
   PubMed Web of Science ®Google Scholar
• LingLNurcombeVCoolSMWnt signaling controls the fate of mesenchymal stem cellsGene20094331–21719135507
   PubMed Web of Science ®Google Scholar
• LiuSDontuGMantleIDHedgehog signaling and bmi-1 regulate self-renewal of normal and malignant human mammary stem cellsCancer Res200666126063607116778178
   PubMed Web of Science ®Google Scholar
• RizzoPOsipoCForemanKRational targeting of Notch signaling in cancerOncogene200827385124513118758481
   PubMed Web of Science ®Google Scholar
• FarnieGClarkeRBMammary stem cells and breast cancer--role of Notch signallingStem Cell Rev20073216917517873349
   PubMed Web of Science ®Google Scholar
• YamanakaSInduction of pluripotent stem cells from mouse fibroblasts by four transcription factorsCell Prolif200841Suppl 1515618181945
   PubMed Web of Science ®Google Scholar
• Rodriguez-PinillaSMSarrioDMoreno-BuenoGSox2: a possible driver of the basal-like phenotype in sporadic breast cancerMod Pathol200720447448117334350
   PubMed Web of Science ®Google Scholar
• ZhangJLiangQLeiYSOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progressionCancer Res201272174597460822787120
   PubMed Web of Science ®Google Scholar
• SaitohMInvolvement of partial EMT in cancer progressionJ Biochem2018164425726429726955
   PubMed Web of Science ®Google Scholar
• O’BrienCAPollettAGallingerSDickJEA human colon cancer cell capable of initiating tumour growth in immunodeficient miceNature2007445712310611017122772
   PubMed Web of Science ®Google Scholar
• ChuthapisithSEreminJEl-SheemeyMEreminOBreast cancer chemoresistance: emerging importance of cancer stem cellsSurg Oncol2010191273219251410
   PubMed Web of Science ®Google Scholar
• RebucciMMichielsCMolecular aspects of cancer cell resistance to chemotherapyBiochem Pharmacol20138591219122623435357
   PubMed Web of Science ®Google Scholar
• Hirschmann-JaxCFosterAEWulfGGA distinct “side population” of cells with high drug efflux capacity in human tumor cellsProc Natl Acad Sci USA200410139142281423315381773
   PubMed Web of Science ®Google Scholar
• HuCLiHLiJAnalysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signalingCarcinogenesis200829122289229718820285
   PubMed Web of Science ®Google Scholar
• GinestierCHurMHCharafe-JauffretEALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcomeCell Stem Cell20071555556718371393
   PubMed Web of Science ®Google Scholar
• CrokerAKAllanALInhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ human breast cancer cellsBreast Cancer Res Treat20121331758721818590
   PubMed Web of Science ®Google Scholar
• EconomopoulouPKaklamaniVGSiziopikouKThe role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapiesOncologist201217111394140122941971
   PubMed Web of Science ®Google Scholar
• Charafe-JauffretEGinestierCIovinoFAldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancerClin Cancer Res2010161455520028757
   PubMed Web of Science ®Google Scholar
• CleversHThe cancer stem cell: premises, promises and challengesNat Med201117331331921386835
   PubMed Web of Science ®Google Scholar
• Maugeri-SaccàMVigneriPde MariaRCancer stem cells and chemosensitivityClin Cancer Res201117154942494721622723
   PubMed Web of Science ®Google Scholar
• EylerCERichJNSurvival of the fittest: cancer stem cells in therapeutic resistance and angiogenesisJ Clin Oncol200826172839284518539962
   PubMed Web of Science ®Google Scholar
• LiHLiuLGuoLHERG K+ channel expression in CD34+/CD38-/CD123(high) cells and primary leukemia cells and analysis of its regulation in leukemia cellsInt J Hematol200887438739218415658
   PubMed Web of Science ®Google Scholar
• LapidotTSirardCVormoorJA cell initiating human acute myeloid leukaemia after transplantation into SCID miceNature199436764646456487509044
   PubMed Web of Science ®Google Scholar
• BonnetDDickJEHuman acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cellNat Med1997377307379212098
   PubMed Web of Science ®Google Scholar
• CollinsATBerryPAHydeCStowerMJMaitlandNJProspective identification of tumorigenic prostate cancer stem cellsCancer Res20056523109461095116322242
   PubMed Web of Science ®Google Scholar
• BapatSAMaliAMKoppikarCBKurreyNKStem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancerCancer Res20056583025302915833827
   PubMed Web of Science ®Google Scholar
• SinghSKHawkinsCClarkeIDIdentification of human brain tumour initiating cellsNature2004432701539640115549107
   PubMed Web of Science ®Google Scholar
• CreightonCJLiXLandisMResidual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating featuresProc Natl Acad Sci USA200910633138201382519666588
   PubMed Web of Science ®Google Scholar
• ShibueTWeinbergRAEMT, CSCs, and drug resistance: the mechanistic link and clinical implicationsNat Rev Clin Oncol2017141061162928397828
   PubMed Web of Science ®Google Scholar
• DesaiSBaraiABukhariABDeASenSα-Actinin-4 confers radio-resistance coupled invasiveness in breast cancer cells through AKT pathwayBiochim Biophys Acta Mol Cell Res20181865119620829055790
   PubMed Web of Science ®Google Scholar
• GuptaSIljinKSaraHFZD4 as a mediator of ERG oncogene-induced Wnt signaling and epithelial-to-mesenchymal transition in human prostate cancer cellsCancer Res201070176735674520713528
   PubMed Web of Science ®Google Scholar
• KarnoubAEDashABVoAPMesenchymal stem cells within tumour stroma promote breast cancer metastasisNature2007449716255756317914389
   PubMed Web of Science ®Google Scholar
• LiuSGinestierCOuSJBreast cancer stem cells are regulated by mesenchymal stem cells through cytokine networksCancer Res201171261462421224357
   PubMed Web of Science ®Google Scholar
• LimPKBlissSAPatelSAGap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cellsCancer Res20117151550156021343399
   PubMed Web of Science ®Google Scholar
• PittengerMFMackayAMBeckSCMultilineage potential of adult human mesenchymal stem cellsScience1999284541114314710102814
   PubMed Web of Science ®Google Scholar
• GabbianiGMajnoGDupuytren’s contracture: fibroblast contraction? An ultrastructural studyAm J Pathol19726611311465009249
   PubMed Web of Science ®Google Scholar
• StueltenCHBarbulABuschJIAcute wounds accelerate tumorigenesis by a T cell-dependent mechanismCancer Res200868187278728218794114
   PubMed Web of Science ®Google Scholar
• HuMYaoJCaiLDistinct epigenetic changes in the stromal cells of breast cancersNat Genet200537889990516007089
   PubMed Web of Science ®Google Scholar
• FarmerPBonnefoiHAnderlePA stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancerNat Med2009151687419122658
   PubMed Web of Science ®Google Scholar
• FinakGBertosNPepinFStromal gene expression predicts clinical outcome in breast cancerNat Med200814551852718438415
   PubMed Web of Science ®Google Scholar
• BierieBMosesHLTumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancerNat Rev Cancer20066750652016794634
   PubMed Web of Science ®Google Scholar
• OrimoAGuptaPBSgroiDCStromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretionCell2005121333534815882617
   PubMed Web of Science ®Google Scholar
• BurgerJAKippsTJCXCR4: a key receptor in the crosstalk between tumor cells and their microenvironmentBlood200610751761176716269611
   PubMed Web of Science ®Google Scholar
• ChuQDPanuLHolmNTHigh chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcomeJ Surg Res2010159268969519500800
   PubMed Web of Science ®Google Scholar
• SchellerJRose-JohnSInterleukin-6 and its receptor: from bench to bedsideMed Microbiol Immunol2006195417318316741736
   PubMed Web of Science ®Google Scholar
• WaughDJWilsonCThe interleukin-8 pathway in cancerClin Cancer Res200814216735674118980965
   PubMed Web of Science ®Google Scholar
• ChaoMPAlizadehAATangCTherapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemiaCancer Res20117141374138421177380
   PubMed Web of Science ®Google Scholar
• BenoyIHSalgadoRvan DamPIncreased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survivalClin Cancer Res200410217157716215534087
   PubMed Web of Science ®Google Scholar
• AraTDeclerckYAInterleukin-6 in bone metastasis and cancer progressionEur J Cancer20104671223123120335016
   PubMed Web of Science ®Google Scholar
• IliopoulosDHirschHAStruhlKAn epigenetic switch involving NF-kappaB, Lin28, let-7 microRNA, and IL6 links inflammation to cell transformationCell2009139469370619878981
   PubMed Web of Science ®Google Scholar
• GinestierCLiuSDiebelMECXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenograftsJ Clin Invest2010120248549720051626
   PubMed Web of Science ®Google Scholar
• BarnesPJKarinMNuclear factor-κB – a pivotal transcription factor in chronic inflammatory diseasesN Engl J Med199733615106610719091804
   PubMed Web of Science ®Google Scholar
• MichieliPMazzoneMBasilicoCTargeting the tumor and its microenvironment by a dual-function decoy Met receptorCancer Cell200461617315261142
   PubMed Web of Science ®Google Scholar
• VermeulenLde SousaEMeloFvan der HeijdenMWnt activity defines colon cancer stem cells and is regulated by the microenvironmentNat Cell Biol201012546847620418870
   PubMed Web of Science ®Google Scholar
• FillmoreCMGuptaPBRudnickJAEstrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signalingProc Natl Acad Sci USA201010750217372174221098263
   PubMed Web of Science ®Google Scholar
• DufraineJFunahashiYKitajewskiJNotch signaling regulates tumor angiogenesis by diverse mechanismsOncogene200827385132513718758482
   PubMed Web of Science ®Google Scholar
• HiscoxSParrCNakamuraTInhibition of HGF/SF-induced breast cancer cell motility and invasion by the HGF/SF variant, NK4Breast Cancer Res Treat200059324525410832594
   PubMed Web of Science ®Google Scholar
• LebedisCChenKFallavollitaLBoutrosTBrodtPPeripheral lymph node stromal cells can promote growth and tumorigenicity of breast carcinoma cells through the release of IGF-I and EGFInt J Cancer200210012812115579
   PubMed Web of Science ®Google Scholar
• PietrasKRubinKSjöblomTInhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapyCancer Res200262195476548412359756
   PubMed Web of Science ®Google Scholar
• SingerCFKronsteinerNMartonEMMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactionsBreast Cancer Res Treat2002721697712000221
   PubMed Web of Science ®Google Scholar
• DaleTCWeber-HallSJSmithKCompartment switching of Wnt-2 expression in human breast tumorsCancer Res19965619432043238813115
   PubMed Web of Science ®Google Scholar
• SugiyamaTKoharaHNodaMNagasawaTMaintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemo-kine signaling in bone marrow stromal cell nichesImmunity200625697798817174120
   PubMed Web of Science ®Google Scholar
• CalabreseCPoppletonHKocakMA perivascular niche for brain tumor stem cellsCancer Cell2007111698217222791
   PubMed Web of Science ®Google Scholar
• BhatiRPattersonCLivasyCAMolecular characterization of human breast tumor vascular cellsAm J Pathol200817251381139018403594
   PubMed Web of Science ®Google Scholar
• KeithBSimonMCHypoxia-inducible factors, stem cells, and cancerCell2007129346547217482542
   PubMed Web of Science ®Google Scholar
• HolashJWiegandSJYancopoulosGDNew model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGFOncogene199918385356536210498889
   PubMed Web of Science ®Google Scholar
• MillerKWangMGralowJPaclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerN Engl J Med Overseas Ed20073572626662676
   PubMed Web of Science ®Google Scholar
• PetrelliFBarniSBevacizumab in advanced breast cancer: an opportunity as second-line therapy?Med Oncol20122911421161443
   PubMed Web of Science ®Google Scholar
• Pàez-RibesMAllenEHudockJAntiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasisCancer Cell200915322023119249680
   PubMed Web of Science ®Google Scholar
• EbosJMLeeCRCruz-MunozWAccelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesisCancer Cell200915323223919249681
   PubMed Web of Science ®Google Scholar
• SantosSJKakaralaPHeathAClouthierSWichaMSAbstract 3336: anti-angiogenic agents increase breast cancer stem cells via generation of tumor hypoxiaCancer Res2011718 Supplement3336
   Web of Science ®Google Scholar
• ShojaeiFLeeJHSimmonsBHHGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumorsCancer Res20107024100901010020952508
   PubMed Web of Science ®Google Scholar
• SorianoJVUyttendaeleHKitajewskiJMontesanoRExpression of an activated Notch4(int-3) oncoprotein disrupts morphogenesis and induces an invasive phenotype in mammary epithelial cells in vitroInt J Cancer200086565265910797286
   PubMed Web of Science ®Google Scholar
• UyttendaeleHSorianoJVMontesanoRKitajewskiJNotch4 and Wnt-1 proteins function to regulate branching morphogenesis of mammary epithelial cells in an opposing fashionDev Biol199819622042179576833
   PubMed Web of Science ®Google Scholar
• Coleman-VaughanCMalADeAMcCarthyJVThe $γ$-Secretase Protease Complexes in Neurodegeneration, Cancer and Immunity. In Chakraborti S, Dhalla NS, editorsPathophysiological Aspects of ProteasesSingaporeSpringer20174787
   Google Scholar
• MilanoJMckayJDagenaisCModulation of Notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiationToxicol Sci200482134135815319485
   PubMed Web of Science ®Google Scholar
• RealPJFerrandoAANotch inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemiaLeukemia20092381374137719357700
   PubMed Web of Science ®Google Scholar
• TianHCallahanCADupreeKJHedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesisProc Natl Acad Sci USA2009106114254425919246386
   PubMed Web of Science ®Google Scholar
• von HoffDDLorussoPMRudinCMInhibition of the hedgehog pathway in advanced basal-cell carcinomaN Engl J Med2009361121164117219726763
   PubMed Web of Science ®Google Scholar
• NagataYLanKHZhouXPTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell20046211712715324695
   PubMed Web of Science ®Google Scholar
• KorkayaHPaulsonACharafe-JauffretERegulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signalingPLoS Biol200976e100012119492080
   PubMed Web of Science ®Google Scholar
• KochharRKhuranaVBejjankiHCalditoGFortCStatins to reduce breast cancer risk: a case control study in U.S. female veteransJ Clin Oncol20052316_suppl514514
   Web of Science ®Google Scholar
• RidkerPMCannonCPMorrowDC-reactive protein levels and outcomes after statin therapyN Engl J Med20053521202815635109
   PubMed Web of Science ®Google Scholar
• KastritisECharidimouAVarkarisADimopoulosMATargeted therapies in multiple myelomaTarg Oncol2009412336
   Web of Science ®Google Scholar
• MercierICasimiroMCWangCHuman breast cancer-associated fibroblasts (CAFs) show caveolin-1 down-regulation and Rb tumor suppressor functional inactivation: implications for the response to hormonal therapyCancer Biol Ther2008781212122518458534
   PubMed Web of Science ®Google Scholar
• DittmerAFuchsAOerleckeIMesenchymal stem cells and carcinoma-associated fibroblasts sensitize breast cancer cells in 3D cultures to kinase inhibitorsInt J Oncol201139368969621667024
   PubMed Web of Science ®Google Scholar
• LuXKangYChemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and boneJ Biol Chem200928442290872909619720836
   PubMed Web of Science ®Google Scholar
• LiQXiaJYaoYSulforaphane inhibits mammary adipogenesis by targeting adipose mesenchymal stem cellsBreast Cancer Res Treat2013141231732424002734
   PubMed Web of Science ®Google Scholar
• RahmanMPumphreyJGLipkowitzSThe TRAIL to targeted therapy of breast cancerAdv Cancer Res2009103437319854352
   PubMed Web of Science ®Google Scholar
• PiggottLOmidvarNPérezSMEberlMClarksonRWESuppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAILBreast Cancer Res2011135R8821914219
   PubMed Web of Science ®Google Scholar
• LiguoriMBuracchiCPasqualiniFFunctional TRAIL receptors in monocytes and tumor-associated macrophages: a possible targeting pathway in the tumor microenvironmentOncotarget2016727416624167627191500
   PubMedGoogle Scholar
• de FrancescoEMSotgiaFLisantiMPCancer stem cells (CSCs): metabolic strategies for their identification and eradicationBiochem J201847591611163429743249
   PubMed Web of Science ®Google Scholar
• DeshmukhADeshpandeKArfusoFNewsholmePDharmarajanACancer stem cell metabolism: a potential target for cancer therapyMol Cancer20161516927825361
   PubMed Web of Science ®Google Scholar
• SnyderVReed-NewmanTCArnoldLThomasSMAnantSCancer stem cell metabolism and potential therapeutic targetsFront Oncol2018820329922594
   PubMed Web of Science ®Google Scholar
• SanchoPBurgos-RamosETaveraAMYC/PGC-1α balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cellsCell Metab201522459060526365176
   PubMed Web of Science ®Google Scholar
• ManciniRNotoAPisanuMEMetabolic features of cancer stem cells: the emerging role of lipid metabolismOncogene201837182367237829445137
   PubMed Web of Science ®Google Scholar
• de FrancescoEMMaggioliniMTanowitzHBSotgiaFLisantiMPTargeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for optimizing anti-angiogenic therapyOncotarget2017834561265614228915578
   PubMedGoogle Scholar
• ZhangXFryknäsMHernlundEInduction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironmentsNat Commun201451329524548894
   PubMed Web of Science ®Google Scholar
• JangamreddyJRGhavamiSGrabarekJSalinomycin induces activation of autophagy, mitophagy and affects mitochondrial polarity: differences between primary and cancer cellsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research2013183392057206923639289
   PubMed Web of Science ®Google Scholar
• DeshmukhAArfusoFNewsholmePDharmarajanARegulation of cancer stem cell metabolism by secreted frizzled-related protein 4 (sFRP4)Cancers201810240
   Web of Science ®Google Scholar
• El HoutMdos SantosLHamaïAMehrpourMA promising new approach to cancer therapy: targeting iron metabolism in cancer stem cellsSemin Cancer Biol20185312513830071257
   PubMed Web of Science ®Google Scholar
• WuDSiMXueHYWongHLNanomedicine applications in the treatment of breast cancer: current state of the artInt J Nanomedicine2017125879589228860754
   PubMed Web of Science ®Google Scholar
• HongISJangGBLeeHYNamJSTargeting cancer stem cells by using the nanoparticlesInt J Nanomedicine201510Spec Iss25126026425092
   PubMed Web of Science ®Google Scholar
• SunRShenSZhangYJNanoparticle-facilitated autophagy inhibition promotes the efficacy of chemotherapeutics against breast cancer stem cellsBiomaterials2016103445527376558
   PubMed Web of Science ®Google Scholar
• LiSYSunRWangHXCombination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cellsJ Control Release201520571425445694
   PubMed Web of Science ®Google Scholar
• AhmadAMondalSKMukhopadhyayDBanerjeeRAlkharfyKMDevelopment of liposomal formulation for delivering anticancer drug to breast cancer Stem-Cell-Like cells and its pharmacokinetics in an animal modelMol Pharm20161331081108826832839
   PubMed Web of Science ®Google Scholar
• ZuoZQChenKGYuXYPromoting tumor penetration of nanoparticles for cancer stem cell therapy by TGF-β signaling pathway inhibitionBiomaterials201682485926751819
   PubMed Web of Science ®Google Scholar
• PramanikDCampbellNRKarikariCRestitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in miceMol Cancer Ther20111081470148021622730
   PubMed Web of Science ®Google Scholar
• FiorilloMVerreAFIliutMGraphene oxide selectively targets cancer stem cells, across multiple tumor types: implications for non-toxic cancer treatment, via “differentiation-based nano-therapy”Oncotarget2015663553356225708684
   PubMedGoogle Scholar
• BurkeARSinghRNCarrollDLThe resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapyBiomaterials201233102961297022245557
   PubMed Web of Science ®Google Scholar
• MukherjeeANarayanKPPalKSelective cancer targeting via aberrant behavior of cancer cell-associated glucocorticoid receptorMol Ther200917462363119223869
   PubMed Web of Science ®Google Scholar